ES2109752T3 - Medicamento para tratamiento terapeutico y profilactico de enfermedades causadas por hiperplasia de las celulas de los musculos lisos. - Google Patents

Medicamento para tratamiento terapeutico y profilactico de enfermedades causadas por hiperplasia de las celulas de los musculos lisos.

Info

Publication number
ES2109752T3
ES2109752T3 ES95107372T ES95107372T ES2109752T3 ES 2109752 T3 ES2109752 T3 ES 2109752T3 ES 95107372 T ES95107372 T ES 95107372T ES 95107372 T ES95107372 T ES 95107372T ES 2109752 T3 ES2109752 T3 ES 2109752T3
Authority
ES
Spain
Prior art keywords
therapeutic
smooth muscle
prophylactic treatment
hyperplasia
medication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95107372T
Other languages
English (en)
Inventor
Kumi Yamada
Yoshikuni Tamao
Masahiro Ohshima
Norimichi Iwase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Application granted granted Critical
Publication of ES2109752T3 publication Critical patent/ES2109752T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTA UN MEDICAMENTO PARA EL TRATAMIENTO TERAPEUTICO Y PROFILACTICO DE UNA ENFERMEDAD PROVOCADA POR LA HIPERPLASIA DE LAS CELULAS DE LOS MUSCULOS LISOS QUE COMPRENDE COMO INGREDIENTE ACTIVO UN DERIVADO DEL AMINOPIRIDACINA O UNA SAL DEL MISMO REPRESENTADA POR LA SIGUIENTE FORMULA (I), POR EJEMPLO (R) -1(CICLOHEXILYETILAMINO)-4-FENILFTALAZINA.
ES95107372T 1994-05-19 1995-05-16 Medicamento para tratamiento terapeutico y profilactico de enfermedades causadas por hiperplasia de las celulas de los musculos lisos. Expired - Lifetime ES2109752T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10536794 1994-05-19

Publications (1)

Publication Number Publication Date
ES2109752T3 true ES2109752T3 (es) 1998-01-16

Family

ID=14405751

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95107372T Expired - Lifetime ES2109752T3 (es) 1994-05-19 1995-05-16 Medicamento para tratamiento terapeutico y profilactico de enfermedades causadas por hiperplasia de las celulas de los musculos lisos.

Country Status (9)

Country Link
US (1) US5643911A (es)
EP (1) EP0682947B1 (es)
CN (1) CN1116526A (es)
AT (1) ATE157871T1 (es)
CA (1) CA2149691A1 (es)
DE (1) DE69500673T2 (es)
DK (1) DK0682947T3 (es)
ES (1) ES2109752T3 (es)
GR (1) GR3025568T3 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716956A (en) * 1995-06-07 1998-02-10 Bearsden Bearsden Bio, Inc. Dihydrophthalazine antagonists of excitatory amino acid receptors
CN1103591C (zh) * 1996-05-22 2003-03-26 永光制药有限公司 取代的1,4,5,6－四氢哒嗪并[4,5－c]哒嗪－5－酮类化合物之药物组合物及其应用和制备方法
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6903101B1 (en) 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
PT1847534E (pt) * 2001-12-11 2011-08-01 Kyowa Hakko Kirin Co Ltd Derivado de tiadiozolina para o tratamento do cancro
JP4777655B2 (ja) 2002-11-08 2011-09-21 タイコ ヘルスケア グループ エルピー 自己シール性カニューレ
JPWO2004089412A1 (ja) * 2003-04-08 2006-07-06 三菱ウェルファーマ株式会社 特異的ｎａｄ（ｐ）ｈオキシダーゼ抑制剤
CN101787000B (zh) 2003-04-18 2011-08-03 协和发酵麒麟株式会社 M期驱动蛋白抑制剂
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
WO2006101103A1 (ja) * 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. 造血器腫瘍治療剤
CA2602397A1 (en) * 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for solid tumor
US7910611B2 (en) * 2005-06-24 2011-03-22 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for restenosis
US8025640B2 (en) 2008-06-27 2011-09-27 Tyco Healthcare Group Lp Pressurized surgical valve

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3738371A (en) 1970-12-11 1973-06-12 Esb Inc Cardiac pacers with source condition-responsive rate
JPS5653659A (en) 1979-10-09 1981-05-13 Mitsubishi Yuka Yakuhin Kk Blood platelet coagulation suppressing agent
JPS5653660A (en) 1979-10-09 1981-05-13 Mitsubishi Yuka Yakuhin Kk 4-phenylphthalazine derivative
JPS5748972A (en) 1980-09-10 1982-03-20 Mitsubishi Yuka Yakuhin Kk 4-phenylphthalazine derivative
JPS5738715A (en) 1980-08-18 1982-03-03 Mochida Pharmaceut Co Ltd Medical composition having activity of prohibiting artery wall from thickening
JPS60218377A (ja) 1984-04-16 1985-11-01 Mitsubishi Yuka Yakuhin Kk ４−フエニルフタラジン誘導体及びそれを有効成分とする循環改善剤
JPS60243074A (ja) 1985-04-15 1985-12-03 Mitsubishi Yuka Yakuhin Kk ４−フエニルフタラジン誘導体
ZA896851B (en) 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors
DE3926606A1 (de) 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
JPH0383923A (ja) 1989-08-25 1991-04-09 Terumo Corp 中膜平滑筋細胞の遊走阻害剤
JPH03106873A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―ピリジルフタラジン誘導体及びそれらを含有する血小板凝集抑制剤
JP2852538B2 (ja) 1989-09-29 1999-02-03 第一製薬株式会社 〔１，２，４〕トリアゾロ〔１，５―ａ〕ピリミジン誘導体
ATE115136T1 (de) * 1990-03-30 1994-12-15 Mitsubishi Chem Ind 4-phenylphthalazin-derivate.
JPH04211666A (ja) 1990-03-30 1992-08-03 Mitsubishi Kasei Corp ４−フェニルフタラジン誘導体
JP2999808B2 (ja) 1990-08-20 2000-01-17 第一製薬株式会社 ２位置換トリアゾロピリミジン類
JPH04154720A (ja) 1990-10-16 1992-05-27 Terumo Corp カテコール誘導体及びこれを含有する血管壁肥厚防止薬
TW279162B (es) 1991-09-26 1996-06-21 Mitsubishi Chem Corp

Also Published As

Publication number Publication date
EP0682947B1 (en) 1997-09-10
US5643911A (en) 1997-07-01
CN1116526A (zh) 1996-02-14
GR3025568T3 (en) 1998-03-31
DE69500673D1 (de) 1997-10-16
EP0682947A1 (en) 1995-11-22
DE69500673T2 (de) 1998-03-19
ATE157871T1 (de) 1997-09-15
DK0682947T3 (da) 1998-05-04
CA2149691A1 (en) 1995-11-20

Similar Documents

Publication Publication Date Title
DK0509317T3 (da) Lægemidler imod knoglesygdomme
ES2109752T3 (es) Medicamento para tratamiento terapeutico y profilactico de enfermedades causadas por hiperplasia de las celulas de los musculos lisos.
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
DE69131317D1 (de) HIV-Proteaseinhibitoren
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
ATE248837T1 (de) Chinuclidin-acrylamide
DK0950057T3 (da) 3-pyridylenantiomerer og deres anvendelse som analgetika
NO975666D0 (no) Pyrroldovater og medisinsk sammensetning
ES2190647T3 (es) 2',2'-difluoronucleosidos para terapia inmunosupresora y combinaciones farmaceuticas.
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
PT998287E (pt) Utilizacao de levobupivacaina
BR0013793A (pt) Medicamentos profiláticos e terapêuticos para doenças oftálmicas
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
ATE284684T1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
DK0559145T3 (da) Lægemiddel til truende abort
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
FI964303A (fi) Keuhkosydänvian hoitamiseen tarkoitettu aine
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.
AR026242A1 (es) Empleo de 2-amino-3,4-dihidro-quinazolinas para la preparacion de un medicamento para el tratamiento o profilaxis de enfermedades provocadas por estadosisquemicos
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
DE69722630D1 (de) Therapeutisches mittel zur behandlung von nierenerkrankungen
DK653687A (da) Middel til behandling af nyresygdomme

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 682947

Country of ref document: ES